Search - tctmd.com

Displaying 141 - 160 of 313

Sort: Relevancy | Date

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

August 06, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Daily News

Possible Cardiovascular Risk of PPIs Lingers in 2 New Studies

June 18, 2015

News Daily News

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

June 16, 2015

News Daily News

Event Rates Often Overestimated in Cardiovascular Trials

Yael L. Maxwell

June 10, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Daily News

Wide Variability in CAS Outcomes Across Hospitals Not Tied to Procedural Volume

May 27, 2015

News Industry News

New Meta-Analysis On Pitavastatin Demonstrates No Adverse Effect Compared With Placebo Or Other Statins On New-Onset Diabetes In Non-Diabetic Patients At Risk For Cardiovascular Disease

May 04, 2015

News Daily News

High-Sensitivity Troponin Assay More Precisely Calibrates Mortality Risk in Suspected ACS Patients

April 20, 2015

News Daily News

Study Quantifies Costs Arising From Thrombotic Events During PCI for NSTE-ACS

Caitlin E. Cox

April 09, 2015

News Daily News

High-Risk Acute MI Patients Less Likely to Stay on Guideline-Recommended Therapies After Hospital Discharge

Yael L. Maxwell

April 03, 2015

News Daily News

Registry Study: Embolic Protection Does Not Appear to Improve SVG PCI Outcomes

Todd Neale

March 27, 2015

Advertisement

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Possible Cardiovascular Risk of PPIs Lingers in 2 New Studies

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

Event Rates Often Overestimated in Cardiovascular Trials

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Wide Variability in CAS Outcomes Across Hospitals Not Tied to Procedural Volume

New Meta-Analysis On Pitavastatin Demonstrates No Adverse Effect Compared With Placebo Or Other Statins On New-Onset Diabetes In Non-Diabetic Patients At Risk For Cardiovascular Disease

High-Sensitivity Troponin Assay More Precisely Calibrates Mortality Risk in Suspected ACS Patients

Study Quantifies Costs Arising From Thrombotic Events During PCI for NSTE-ACS

High-Risk Acute MI Patients Less Likely to Stay on Guideline-Recommended Therapies After Hospital Discharge

Registry Study: Embolic Protection Does Not Appear to Improve SVG PCI Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content